Published in Eur J Heart Fail on February 01, 2009
Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. J Am Coll Cardiol (2012) 2.56
Cardiac dysfunction and noncardiac dysfunction as precursors of heart failure with reduced and preserved ejection fraction in the community. Circulation (2011) 2.00
Early and Long-term Outcomes of Older Adults after Acute Care Encounters for Chronic Obstructive Pulmonary Disease Exacerbation. Ann Am Thorac Soc (2015) 1.93
COPD is associated with cognitive dysfunction and poor physical fitness in heart failure. Heart Lung (2014) 1.41
Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction. J Am Coll Cardiol (2014) 1.27
Airflow obstruction, lung function, and risk of incident heart failure: the Atherosclerosis Risk in Communities (ARIC) study. Eur J Heart Fail (2012) 1.27
Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents. Respir Res (2010) 1.21
The association between COPD and heart failure risk: a review. Int J Chron Obstruct Pulmon Dis (2013) 1.06
The burden of chronic obstructive pulmonary disease in patients hospitalized with heart failure. Wien Klin Wochenschr (2009) 1.02
Right ventricular function in children with bronchial asthma: a tissue Doppler echocardiographic study. Pediatr Cardiol (2010) 0.98
Exercise intolerance in heart failure with preserved ejection fraction: more than a heart problem. J Geriatr Cardiol (2015) 0.95
Epidemiology and aetiology of heart failure. Nat Rev Cardiol (2016) 0.93
Heart failure with preserved ejection fraction in the elderly: scope of the problem. J Mol Cell Cardiol (2015) 0.93
Impact of COPD on the mortality and treatment of patients hospitalized with acute decompensated heart failure: the Worcester Heart Failure Study. Chest (2015) 0.92
Acute decompensated heart failure is routinely treated as a cardiopulmonary syndrome. PLoS One (2013) 0.92
Noncardiac comorbidities and acute heart failure patients. Heart Fail Clin (2013) 0.92
The Saudi Guidelines for the Diagnosis and Management of COPD. Ann Thorac Med (2014) 0.92
Neurohormonal activation and inflammation in chronic cardiopulmonary disease: a brief systematic review. Wien Klin Wochenschr (2009) 0.91
Recent trends in the characteristics and prognosis of patients hospitalized with acute heart failure. Clin Epidemiol (2011) 0.91
Geriatric chest imaging: when and how to image the elderly lung, age-related changes, and common pathologies. Radiol Res Pract (2013) 0.90
Exploring joint disease risk prediction. AMIA Annu Symp Proc (2014) 0.90
The cardiorenal syndrome in heart failure: cardiac? renal? syndrome? Heart Fail Rev (2012) 0.88
Impact of chronic obstructive pulmonary disease severity on symptoms and prognosis in patients with systolic heart failure. Clin Res Cardiol (2012) 0.85
Acute exacerbation of chronic obstructive pulmonary disease: cardiovascular links. Biomed Res Int (2014) 0.85
Differences in clinical characteristics, management and short-term outcome between acute heart failure patients chronic obstructive pulmonary disease and those without this co-morbidity. Clin Res Cardiol (2014) 0.84
Prognostic value of alveolar volume in systolic heart failure: a prospective observational study. BMC Pulm Med (2013) 0.81
Update in diagnosis and therapy of coexistent chronic obstructive pulmonary disease and chronic heart failure. J Thorac Dis (2012) 0.80
Heart failure in elderly: progress in clinical evaluation and therapeutic approach. J Geriatr Cardiol (2013) 0.80
Impact of β-blocker selectivity on long-term outcomes in congestive heart failure patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis (2015) 0.80
Impact of beta2-agonists, beta-blockers, and their combination on cardiac function in elderly male patients with chronic obstructive pulmonary disease. Clin Interv Aging (2013) 0.79
Underuse of β-blockers in heart failure and chronic obstructive pulmonary disease. Heart (2016) 0.78
Non-cardiovascular comorbidity, severity and prognosis in non-selected heart failure populations: A systematic review and meta-analysis. Int J Cardiol (2015) 0.78
Co-morbidities in heart failure. Heart Fail Rev (2014) 0.78
Treatment for Multiple Acute Cardiopulmonary Conditions in Older Adults Hospitalized with Pneumonia, Chronic Obstructive Pulmonary Disease, or Heart Failure. J Am Geriatr Soc (2016) 0.77
Office-Based Case Finding for Chronic Obstructive Pulmonary Disease in Older Adults in Primary Care. Can Respir J (2016) 0.77
Considerations for initial therapy in the treatment of acute heart failure. Crit Care (2015) 0.76
Echocardiography, spirometry, and systemic acute-phase inflammatory proteins in smokers with COPD or CHF: an observational study. PLoS One (2013) 0.76
Examination of pulse oximetry tracings to detect obstructive sleep apnea in patients with advanced chronic obstructive pulmonary disease. Can Respir J (2014) 0.76
B-type natriuretic peptides in chronic obstructive pulmonary disease: a systematic review. BMC Pulm Med (2017) 0.75
Factors associated with prolonged hospitalization, readmission, and death in elderly heart failure patients in western Romania. Clin Interv Aging (2015) 0.75
Serial pulmonary function tests to diagnose COPD in chronic heart failure. Transl Respir Med (2014) 0.75
Impact of roflumilast on exacerbations of COPD, health care utilization, and costs in a predominantly elderly Medicare Advantage population. Int J Chron Obstruct Pulmon Dis (2015) 0.75
A Gordian knot: disentangling comorbidities in heart failure. Eur J Heart Fail (2016) 0.75
COPD advances in left ventricular diastolic dysfunction. Int J Chron Obstruct Pulmon Dis (2016) 0.75
Telerehabilitation for patients with heart failure. Cardiovasc Diagn Ther (2015) 0.75
Patients with heart failure and concomitant chronic obstructive pulmonary disease participating in the Heart Failure Pilot Survey (ESC-HF Pilot) - Polish population. Arch Med Sci (2015) 0.75
Expert consensus document: Echocardiography and lung ultrasonography for the assessment and management of acute heart failure. Nat Rev Cardiol (2017) 0.75
Influence of heart failure on resting lung volumes in patients with COPD. J Bras Pneumol (2016) 0.75
The Yin and Yang of dyspnea in the emergency department: heart failure or COPD? Clinics (Sao Paulo) (2013) 0.75
Health status in patients with coexistent COPD and heart failure: a validation and comparison between the Clinical COPD Questionnaire and the Minnesota Living with Heart Failure Questionnaire. Int J Chron Obstruct Pulmon Dis (2014) 0.75
COPD in patients with stable heart failure in the primary care setting. Int J Chron Obstruct Pulmon Dis (2015) 0.75
Comparative heart failure profile over a 3-year period in a Romanian general hospital. Clin Interv Aging (2013) 0.75
Standardized evaluation of lung congestion during COPD exacerbation better identifies patients at risk of dying. Int J Chron Obstruct Pulmon Dis (2013) 0.75
Diabetes mellitus in patients with chronic obstructive pulmonary disease-The impact on mortality. PLoS One (2017) 0.75
Initiation of triple therapy maintenance treatment among patients with COPD in the US. Int J Chron Obstruct Pulmon Dis (2016) 0.75
Heart failure and respiratory hospitalizations are reduced in patients with heart failure and chronic obstructive pulmonary disease with the use of an implantable pulmonary artery pressure monitoring device. J Card Fail (2014) 0.75
Heart failure and chronic obstructive pulmonary disease: lung function test interpretation. Eur J Heart Fail (2009) 0.75
Diagnostic and prognostic utility of mid-expiratory flow rate in older community-dwelling persons with respiratory symptoms, but without chronic obstructive pulmonary disease. BMC Pulm Med (2015) 0.75
State of the Art Review of the Right Ventricle in COPD Patients: It is Time to Look Closer. Lung (2016) 0.75
Impact of airflow limitation in chronic heart failure. Neth Heart J (2017) 0.75
Therapeutic effects of the combination of inhaled beta2-agonists and beta-blockers in COPD patients with cardiovascular disease. Heart Fail Rev (2017) 0.75
Atherosclerosis--an inflammatory disease. N Engl J Med (1999) 59.28
Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med (2001) 27.83
Interpretative strategies for lung function tests. Eur Respir J (2005) 21.50
Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J (2004) 16.84
The natural history of congestive heart failure: the Framingham study. N Engl J Med (1971) 13.94
Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med (2002) 12.95
Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med (2006) 10.58
Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J (2005) 7.75
Echocardiography in chronic heart failure in the community. Q J Med (1993) 7.64
Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. JAMA (2003) 6.39
Systolic and diastolic heart failure in the community. JAMA (2006) 5.99
Predictors of congestive heart failure in the elderly: the Cardiovascular Health Study. J Am Coll Cardiol (2000) 5.59
Cardiovascular magnetic resonance, fibrosis, and prognosis in dilated cardiomyopathy. J Am Coll Cardiol (2006) 5.58
The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. N Engl J Med (1994) 5.38
Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study. Arch Intern Med (2001) 4.81
Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation (2003) 4.63
Congestive heart failure in the community: a study of all incident cases in Olmsted County, Minnesota, in 1991. Circulation (1998) 4.63
EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. Eur Heart J (2006) 4.57
Noncardiac comorbidity increases preventable hospitalizations and mortality among Medicare beneficiaries with chronic heart failure. J Am Coll Cardiol (2003) 4.57
An administrative claims model suitable for profiling hospital performance based on 30-day mortality rates among patients with heart failure. Circulation (2006) 4.52
Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12 065 patients with new-onset heart failure. Circulation (2003) 4.43
The relationship between reduced lung function and cardiovascular mortality: a population-based study and a systematic review of the literature. Chest (2005) 4.41
Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study. Circulation (2003) 4.09
Epidemiology and costs of chronic obstructive pulmonary disease. Eur Respir J (2006) 3.89
Unrecognized heart failure in elderly patients with stable chronic obstructive pulmonary disease. Eur Heart J (2005) 3.58
Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA (2004) 3.39
Hospitalization of patients with heart failure: National Hospital Discharge Survey, 1985 to 1995. Am Heart J (1999) 3.38
B-type natriuretic peptide strongly reflects diastolic wall stress in patients with chronic heart failure: comparison between systolic and diastolic heart failure. J Am Coll Cardiol (2006) 3.37
Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. Am J Respir Crit Care Med (2002) 3.32
Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA (2002) 3.24
Clinical indications for cardiovascular magnetic resonance (CMR): Consensus Panel report. Eur Heart J (2004) 3.19
Prognosis and determinants of survival in patients newly hospitalized for heart failure: a population-based study. Arch Intern Med (2002) 3.09
Risk of over-diagnosis of COPD in asymptomatic elderly never-smokers. Eur Respir J (2002) 3.06
Utility of B-natriuretic peptide in detecting diastolic dysfunction: comparison with Doppler velocity recordings. Circulation (2002) 3.04
Prognosis of heart failure with preserved ejection fraction: a 5 year prospective population-based study. Eur Heart J (2007) 2.99
Importance of heart failure with preserved systolic function in patients > or = 65 years of age. CHS Research Group. Cardiovascular Health Study. Am J Cardiol (2001) 2.93
NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. Eur Heart J (2005) 2.93
Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea. J Am Coll Cardiol (2002) 2.83
Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation (2000) 2.78
Assessment of systolic left ventricular function: a multi-centre comparison of cineventriculography, cardiac magnetic resonance imaging, unenhanced and contrast-enhanced echocardiography. Eur Heart J (2004) 2.68
Precipitating factors leading to decompensation of heart failure. Traits among urban blacks. Arch Intern Med (1988) 2.65
Care and outcomes of patients newly hospitalized for heart failure in the community treated by cardiologists compared with other specialists. Circulation (2003) 2.61
Changing incidence and survival for heart failure in a well-defined older population, 1970-1974 and 1990-1994. Circulation (2006) 2.53
Factors contributing to the hospitalization of patients with congestive heart failure. Am J Public Health (1997) 2.51
Gender, age, and heart failure with preserved left ventricular systolic function. J Am Coll Cardiol (2003) 2.46
C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease. Thorax (2006) 2.38
Bedside B-Type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction. Results from the Breathing Not Properly Multinational Study. J Am Coll Cardiol (2003) 2.34
Lung function and exercise gas exchange in chronic heart failure. Circulation (1997) 2.32
Clinical outcome with enalapril in symptomatic chronic heart failure; a dose comparison. The NETWORK Investigators. Eur Heart J (1998) 2.30
Right and left ventricular dysfunction in patients with severe pulmonary disease. Chest (1998) 2.27
Chronic obstructive pulmonary disease as a risk factor for cardiovascular morbidity and mortality. Proc Am Thorac Soc (2005) 2.17
National trends in outcomes among elderly patients with heart failure. Am J Med (2006) 2.13
Acute precipitants of congestive heart failure exacerbations. Arch Intern Med (2001) 2.11
Population impact of different definitions of airway obstruction. Eur Respir J (2003) 2.11
Discrepancy in the use of confirmatory tests in patients hospitalized with the diagnosis of chronic obstructive pulmonary disease or congestive heart failure. Respir Care (2006) 2.00
Survival associated with two sets of diagnostic criteria for congestive heart failure. Am J Epidemiol (2004) 1.99
Physiology and pathophysiology of pleural fluid turnover. Eur Respir J (1997) 1.94
Influence of concomitant disease on patterns of hospitalization in patients with heart failure discharged from Scottish hospitals in 1995. Eur Heart J (1998) 1.94
Uncovering heart failure in patients with a history of pulmonary disease: rationale for the early use of B-type natriuretic peptide in the emergency department. Acad Emerg Med (2003) 1.91
Prediction of hospital readmission for heart failure: development of a simple risk score based on administrative data. J Am Coll Cardiol (1999) 1.89
Congestive heart failure hospitalizations and survival in California: patterns according to race/ethnicity. Am Heart J (1999) 1.82
Long-term survival after heart failure: a contemporary population-based perspective. Arch Intern Med (2007) 1.81
Characteristics, outcomes, and predictors of 1-year mortality in patients hospitalized for acute heart failure. Eur Heart J (2006) 1.80
Hospitalized congestive heart failure patients with preserved versus abnormal left ventricular systolic function: clinical characteristics and drug therapy. Am J Med (1995) 1.73
Heart failure and chronic obstructive pulmonary disease: An ignored combination? Eur J Heart Fail (2006) 1.68
Congestive heart failure with preserved systolic function in a statewide sample of community hospitals. J Card Fail (2001) 1.68
Abnormal pulmonary function specifically related to congestive heart failure: comparison of patients before and after cardiac transplantation. Am J Med (1990) 1.67
BNP Consensus Panel 2004: A clinical approach for the diagnostic, prognostic, screening, treatment monitoring, and therapeutic roles of natriuretic peptides in cardiovascular diseases. Congest Heart Fail (2004) 1.66
Female sex is associated with a better long-term survival in patients hospitalized with congestive heart failure. Eur Heart J (2004) 1.65
Respiratory muscle dysfunction in congestive heart failure: clinical correlation and prognostic significance. Circulation (2001) 1.64
Spectrum of heart failure in older patients: results from the National Heart Failure project. Am Heart J (2002) 1.63
Prognosis of congestive heart failure in patients with normal versus reduced ejection fractions: results from a cohort of 2,258 hospitalized patients. J Card Fail (2003) 1.58
Differences between patients with heart failure treated by cardiologists, internists, family physicians, and other physicians: analysis of a large, statewide database. Am Heart J (2000) 1.56
The Warfarin and Antiplatelet Therapy in Heart Failure trial (WATCH): rationale, design, and baseline patient characteristics. J Card Fail (2004) 1.54
Bronchial hyperresponsiveness to inhaled methacholine in subjects with chronic left heart failure at a time of exacerbation and after increasing diuretic therapy. Chest (1989) 1.52
Case management in a heterogeneous congestive heart failure population: a randomized controlled trial. Arch Intern Med (2003) 1.47
Administration of an intravenous perfluorocarbon contrast agent improves echocardiographic determination of left ventricular volumes and ejection fraction: comparison with cine magnetic resonance imaging. J Am Coll Cardiol (1998) 1.46
Heart failure in the general population of men--morbidity, risk factors and prognosis. J Intern Med (2001) 1.46
Potential role of human visceral pleura in pleural fluid turnover. Chin Med J (Engl) (2006) 1.44
Concomitant factors of decompensation in chronic heart failure. Am J Cardiol (1996) 1.42
Predicting mortality in patients with heart failure: a pragmatic approach. Heart (2003) 1.42
Heart failure with preserved left ventricular systolic function: a hospital cohort study. Heart (2005) 1.39
Left atrial and ventricular filling in chronic obstructive pulmonary disease. An echocardiographic and Doppler study. Am J Respir Crit Care Med (2000) 1.38
Cardiology participation improves outcomes in patients with new-onset heart failure in the outpatient setting. J Am Coll Cardiol (2003) 1.38
Prognostic importance of pulmonary hypertension in patients with heart failure. Am J Cardiol (2007) 1.37
Costs for heart failure with normal vs reduced ejection fraction. Arch Intern Med (2006) 1.36
Randomized Trial of Telephone Intervention in Chronic Heart Failure (DIAL): study design and preliminary observations. J Card Fail (2003) 1.35
Nationwide survey on acute heart failure in cardiology ward services in Italy. Eur Heart J (2006) 1.30
Long-term costs and resource use in elderly participants with congestive heart failure in the Cardiovascular Health Study. Am Heart J (2007) 1.29
Long-term survival in patients hospitalized with congestive heart failure: relation to preserved and reduced left ventricular systolic function. Eur Heart J (2003) 1.27
Brain natriuretic peptide is a prognostic parameter in chronic lung disease. Am J Respir Crit Care Med (2006) 1.26
Heart failure in a cold climate. Seasonal variation in heart failure-related morbidity and mortality. J Am Coll Cardiol (2002) 1.23
Mortality trends for 23,505 Medicare patients hospitalized with heart failure in Northeast Ohio, 1991 to 1997. Am Heart J (2003) 1.21
Ten-year trends in hospital care for congestive heart failure: improved outcomes and increased use of resources. Arch Intern Med (2000) 1.20
Correlates and outcomes of preserved left ventricular systolic function among older adults hospitalized with heart failure. Am Heart J (2002) 1.18
Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2011) 23.50
Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med (2010) 14.43
A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med (2009) 14.13
Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med (2005) 12.46
2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2013) 11.88
Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med (2003) 10.57
Coronary-artery bypass surgery in patients with left ventricular dysfunction. N Engl J Med (2011) 10.29
2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation (2013) 10.07
Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet (2003) 9.98
Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med (2012) 9.46
Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med (2004) 9.13
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet (2009) 8.54
Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet (2003) 8.12
Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med (2012) 7.93
Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis. N Engl J Med (2007) 7.86
Rosuvastatin in older patients with systolic heart failure. N Engl J Med (2007) 7.55
Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. N Engl J Med (2005) 6.86
A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med (2002) 5.55
Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med (2010) 5.48
Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARM Program and the Duke Databank. J Am Coll Cardiol (2007) 4.74
Treatment of anemia with darbepoetin alfa in systolic heart failure. N Engl J Med (2013) 4.67
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. N Engl J Med (2015) 4.56
Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. Eur J Heart Fail (2010) 3.90
2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation (2013) 3.86
Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation (2006) 3.85
Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial. Lancet (2005) 3.67
The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet (2012) 3.66
Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med (2008) 3.49
Digoxin reduces 30-day all-cause hospital admission in older patients with chronic systolic heart failure. Am J Med (2013) 3.46
Plasma concentration of amino-terminal pro-brain natriuretic peptide in chronic heart failure: prediction of cardiovascular events and interaction with the effects of rosuvastatin: a report from CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure). J Am Coll Cardiol (2009) 3.32
Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation (2004) 3.30
Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation. Circulation (2013) 3.25
Predictors of mortality and morbidity in patients with chronic heart failure. Eur Heart J (2005) 3.09
Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation (2007) 2.95
N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation). J Am Coll Cardiol (2013) 2.90
Albuminuria in chronic heart failure: prevalence and prognostic importance. Lancet (2009) 2.79
Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulation (2005) 2.78
Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials. Circulation (2004) 2.73
Spectral microvolt T-wave alternans testing has no prognostic value in patients recently hospitalized with decompensated heart failure. Eur J Heart Fail (2013) 2.73
Profile of microvolt T-wave alternans testing in 1003 patients hospitalized with heart failure. Eur J Heart Fail (2012) 2.72
Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation (2006) 2.68
Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial. Eur Heart J (2010) 2.68
Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. J Am Coll Cardiol (2006) 2.68
Assessing and grading congestion in acute heart failure: a scientific statement from the acute heart failure committee of the heart failure association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine. Eur J Heart Fail (2010) 2.64
Long-term trends in first hospitalization for heart failure and subsequent survival between 1986 and 2003: a population study of 5.1 million people. Circulation (2009) 2.60
What have we learned about patients with heart failure and preserved ejection fraction from DIG-PEF, CHARM-preserved, and I-PRESERVE? J Am Coll Cardiol (2012) 2.60
Body mass index and prognosis in patients with chronic heart failure: insights from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation (2007) 2.41
Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies. Eur Heart J (2012) 2.29
Prognostic implications of left ventricular mass and geometry following myocardial infarction: the VALIANT (VALsartan In Acute myocardial iNfarcTion) Echocardiographic Study. JACC Cardiovasc Imaging (2008) 2.24
Effect of antecedent hypertension and follow-up blood pressure on outcomes after high-risk myocardial infarction. Hypertension (2007) 2.22
Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. Am Heart J (2009) 2.21
Galectin-3 and cardiac function in survivors of acute myocardial infarction. Circ Heart Fail (2013) 2.17
A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association Functional Class I or II Heart Failure. J Am Coll Cardiol (2007) 2.15
What works in chronic care management: the case of heart failure. Health Aff (Millwood) (2009) 2.11
Selecting patients for cardiac resynchronization therapy: the fallacy of echocardiographic dyssynchrony. J Am Coll Cardiol (2009) 2.07
Association between cardiac biomarkers and the development of ESRD in patients with type 2 diabetes mellitus, anemia, and CKD. Am J Kidney Dis (2011) 2.05
Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. Nephrol Dial Transplant (2009) 2.02
Pathogenesis of sudden unexpected death in a clinical trial of patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. Circulation (2010) 2.00
Advanced chronic heart failure: A position statement from the Study Group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail (2007) 1.99
Galectin-3 predicts response to statin therapy in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). Eur Heart J (2012) 1.93
Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. Eur J Heart Fail (2009) 1.93
Serum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction. J Am Coll Cardiol (2010) 1.92
Association of forced expiratory volume with disease duration and sputum neutrophils in chronic asthma. Am J Med (2002) 1.87
Stroke in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with Darbepoetin Alfa: the trial to reduce cardiovascular events with Aranesp therapy (TREAT) experience. Circulation (2011) 1.87
Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme. Eur Heart J (2008) 1.84
Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure). J Am Coll Cardiol (2013) 1.83
Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. Am Heart J (2010) 1.82
Awareness and perception of heart failure among European cardiologists, internists, geriatricians, and primary care physicians. Eur Heart J (2008) 1.80
Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure) study. J Am Coll Cardiol (2012) 1.71
Lipid-modifying therapies and risk of pancreatitis: a meta-analysis. JAMA (2012) 1.71
Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebo-controlled trial. Lancet (2008) 1.69
Baseline characteristics in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE). J Renin Angiotensin Aldosterone Syst (2012) 1.68
The prognostic significance of heart failure with preserved left ventricular ejection fraction: a literature-based meta-analysis. Eur J Heart Fail (2009) 1.63
Atrial fibrillation: profile and burden of an evolving epidemic in the 21st century. Int J Cardiol (2013) 1.61
Anemia and its relationship to clinical outcome in heart failure. Circulation (2004) 1.61
Intensive glycemic control has no impact on the risk of heart failure in type 2 diabetic patients: evidence from a 37,229 patient meta-analysis. Am Heart J (2011) 1.59
Palliative care for heart failure. BMJ (2002) 1.57
Assessment of dyspnea in acute decompensated heart failure: insights from ASCEND-HF (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure) on the contributions of peak expiratory flow. J Am Coll Cardiol (2012) 1.56
The inter-relationship of diabetes and left ventricular systolic function on outcome after high-risk myocardial infarction. Eur J Heart Fail (2010) 1.55
Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure: results from the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity) program. J Am Coll Cardiol (2012) 1.55
Neurohormonal activation in acute heart failure: results from VERITAS. Cardiology (2011) 1.51